Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact
Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: PSMC1

Gene summary for PSMC1

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

PSMC1

Gene ID

5700

Gene nameproteasome 26S subunit, ATPase 1
Gene AliasP26S4
Cytomap14q32.11
Gene Typeprotein-coding
GO ID

GO:0006508

UniProtAcc

P62191


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
5700PSMC1LZE2THumanEsophagusESCC1.95e-041.03e+000.082
5700PSMC1LZE4THumanEsophagusESCC1.34e-331.15e+000.0811
5700PSMC1LZE5THumanEsophagusESCC1.60e-078.41e-010.0514
5700PSMC1LZE7THumanEsophagusESCC4.35e-097.28e-010.0667
5700PSMC1LZE8THumanEsophagusESCC1.25e-116.53e-010.067
5700PSMC1LZE20THumanEsophagusESCC3.58e-229.78e-010.0662
5700PSMC1LZE22THumanEsophagusESCC6.91e-087.11e-010.068
5700PSMC1LZE24THumanEsophagusESCC5.30e-299.13e-010.0596
5700PSMC1LZE21THumanEsophagusESCC6.37e-058.66e-010.0655
5700PSMC1LZE6THumanEsophagusESCC3.65e-179.39e-010.0845
5700PSMC1P1T-EHumanEsophagusESCC1.56e-098.04e-010.0875
5700PSMC1P2T-EHumanEsophagusESCC3.37e-561.06e+000.1177
5700PSMC1P4T-EHumanEsophagusESCC2.18e-661.45e+000.1323
5700PSMC1P5T-EHumanEsophagusESCC2.36e-541.13e+000.1327
5700PSMC1P8T-EHumanEsophagusESCC1.52e-621.34e+000.0889
5700PSMC1P9T-EHumanEsophagusESCC1.93e-297.44e-010.1131
5700PSMC1P10T-EHumanEsophagusESCC3.84e-851.51e+000.116
5700PSMC1P11T-EHumanEsophagusESCC2.59e-331.56e+000.1426
5700PSMC1P12T-EHumanEsophagusESCC1.93e-791.67e+000.1122
5700PSMC1P15T-EHumanEsophagusESCC1.81e-832.05e+000.1149
Page: 1 2 3 4 5 6 7 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
LungThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AAH: Atypical adenomatous hyperplasia
AIS: Adenocarcinoma in situ
IAC: Invasive lung adenocarcinoma
MIA: Minimally invasive adenocarcinoma
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ProstateThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.BPH: Benign Prostatic Hyperplasia
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:0010498111EsophagusESCCproteasomal protein catabolic process369/8552490/187231.13e-411.80e-38369
GO:0043161111EsophagusESCCproteasome-mediated ubiquitin-dependent protein catabolic process312/8552412/187233.53e-364.48e-33312
GO:0042176111EsophagusESCCregulation of protein catabolic process280/8552391/187238.65e-262.39e-23280
GO:0009896111EsophagusESCCpositive regulation of catabolic process332/8552492/187234.36e-239.22e-21332
GO:0031331111EsophagusESCCpositive regulation of cellular catabolic process292/8552427/187238.67e-221.53e-19292
GO:1903362111EsophagusESCCregulation of cellular protein catabolic process188/8552255/187235.12e-206.62e-18188
GO:0045862111EsophagusESCCpositive regulation of proteolysis256/8552372/187237.88e-209.43e-18256
GO:1903050111EsophagusESCCregulation of proteolysis involved in cellular protein catabolic process163/8552221/187231.44e-171.27e-15163
GO:0061136111EsophagusESCCregulation of proteasomal protein catabolic process142/8552187/187232.40e-172.00e-15142
GO:0045732111EsophagusESCCpositive regulation of protein catabolic process167/8552231/187231.47e-161.14e-14167
GO:1903364111EsophagusESCCpositive regulation of cellular protein catabolic process117/8552155/187233.25e-141.66e-12117
GO:1901800110EsophagusESCCpositive regulation of proteasomal protein catabolic process91/8552114/187236.74e-143.34e-1291
GO:1903052110EsophagusESCCpositive regulation of proteolysis involved in cellular protein catabolic process101/8552133/187239.58e-134.19e-11101
GO:0070997111EsophagusESCCneuron death216/8552361/187233.49e-086.45e-07216
GO:1901214111EsophagusESCCregulation of neuron death186/8552319/187233.35e-063.73e-05186
GO:190121516EsophagusESCCnegative regulation of neuron death115/8552208/187233.24e-031.34e-02115
GO:001049812LiverCirrhoticproteasomal protein catabolic process216/4634490/187232.52e-219.29e-19216
GO:004217612LiverCirrhoticregulation of protein catabolic process181/4634391/187237.94e-212.77e-18181
GO:000989612LiverCirrhoticpositive regulation of catabolic process215/4634492/187231.13e-203.56e-18215
GO:003133112LiverCirrhoticpositive regulation of cellular catabolic process190/4634427/187231.94e-194.18e-17190
Page: 1 2 3 4 5 6 7 8 9 10 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa05014210EsophagusESCCAmyotrophic lateral sclerosis266/4205364/84651.31e-202.20e-181.13e-18266
hsa05016210EsophagusESCCHuntington disease226/4205306/84651.38e-188.72e-174.46e-17226
hsa05012211EsophagusESCCParkinson disease201/4205266/84651.56e-188.72e-174.46e-17201
hsa05022210EsophagusESCCPathways of neurodegeneration - multiple diseases318/4205476/84656.10e-152.04e-131.05e-13318
hsa05010210EsophagusESCCAlzheimer disease263/4205384/84651.80e-145.47e-132.80e-13263
hsa05169210EsophagusESCCEpstein-Barr virus infection151/4205202/84651.55e-133.45e-121.77e-12151
hsa05020210EsophagusESCCPrion disease193/4205273/84656.42e-131.34e-116.89e-12193
hsa0305028EsophagusESCCProteasome44/420546/84651.05e-111.60e-108.21e-1144
hsa0516510EsophagusESCCHuman papillomavirus infection215/4205331/84657.86e-097.12e-083.65e-08215
hsa0520325EsophagusESCCViral carcinogenesis137/4205204/84652.47e-071.88e-069.62e-07137
hsa0501728EsophagusESCCSpinocerebellar ataxia94/4205143/84656.77e-052.90e-041.48e-0494
hsa0501438EsophagusESCCAmyotrophic lateral sclerosis266/4205364/84651.31e-202.20e-181.13e-18266
hsa0501638EsophagusESCCHuntington disease226/4205306/84651.38e-188.72e-174.46e-17226
hsa05012310EsophagusESCCParkinson disease201/4205266/84651.56e-188.72e-174.46e-17201
hsa0502238EsophagusESCCPathways of neurodegeneration - multiple diseases318/4205476/84656.10e-152.04e-131.05e-13318
hsa0501038EsophagusESCCAlzheimer disease263/4205384/84651.80e-145.47e-132.80e-13263
hsa0516937EsophagusESCCEpstein-Barr virus infection151/4205202/84651.55e-133.45e-121.77e-12151
hsa0502038EsophagusESCCPrion disease193/4205273/84656.42e-131.34e-116.89e-12193
hsa0305037EsophagusESCCProteasome44/420546/84651.05e-111.60e-108.21e-1144
hsa0516515EsophagusESCCHuman papillomavirus infection215/4205331/84657.86e-097.12e-083.65e-08215
Page: 1 2 3 4 5 6 7 8 9 10 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
PSMC1SNVMissense_Mutationrs772023510c.1118N>Tp.Thr373Metp.T373MP62191protein_codingtolerated(0.14)benign(0.047)TCGA-2W-A8YY-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinCR
PSMC1SNVMissense_Mutationc.744N>Cp.Leu248Phep.L248FP62191protein_codingdeleterious(0.02)probably_damaging(1)TCGA-Q1-A73O-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinCR
PSMC1SNVMissense_Mutationc.114N>Cp.Lys38Asnp.K38NP62191protein_codingtolerated(0.05)benign(0.403)TCGA-R2-A69V-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinSD
PSMC1SNVMissense_Mutationrs772023510c.1118N>Tp.Thr373Metp.T373MP62191protein_codingtolerated(0.14)benign(0.047)TCGA-VS-A954-01Cervixcervical & endocervical cancerFemale>=65III/IVChemotherapycisplatinCR
PSMC1SNVMissense_Mutationnovelc.40G>Cp.Gly14Argp.G14RP62191protein_codingtolerated_low_confidence(0.29)probably_damaging(0.953)TCGA-AA-3866-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownSD
PSMC1SNVMissense_Mutationc.788N>Tp.Gly263Valp.G263VP62191protein_codingdeleterious(0)probably_damaging(1)TCGA-AY-6197-01Colorectumcolon adenocarcinomaMale<65I/IIUnknownUnknownSD
PSMC1SNVMissense_Mutationnovelc.100G>Tp.Gly34Trpp.G34WP62191protein_codingdeleterious(0)probably_damaging(0.965)TCGA-CA-6717-01Colorectumcolon adenocarcinomaMale<65I/IIChemotherapyoxaliplatinCR
PSMC1SNVMissense_Mutationnovelc.655C>Tp.Pro219Serp.P219SP62191protein_codingdeleterious(0)probably_damaging(0.924)TCGA-CA-6717-01Colorectumcolon adenocarcinomaMale<65I/IIChemotherapyoxaliplatinCR
PSMC1SNVMissense_Mutationc.829N>Tp.His277Tyrp.H277YP62191protein_codingtolerated(0.25)benign(0.007)TCGA-DY-A1DC-01Colorectumrectum adenocarcinomaFemale>=65I/IIChemotherapycapecitabinePR
PSMC1SNVMissense_Mutationc.643G>Ap.Gly215Serp.G215SP62191protein_codingdeleterious(0)probably_damaging(0.999)TCGA-EF-5830-01Colorectumrectum adenocarcinomaMale<65I/IIUnknownUnknownSD
Page: 1 2 3 4 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
5700PSMC1PROTEASEinhibitorCHEMBL3545432IXAZOMIB CITRATE
5700PSMC1PROTEASEinhibitorCHEMBL451887CARFILZOMIB
5700PSMC1PROTEASEBORTEZOMIBBORTEZOMIB24524217
5700PSMC1PROTEASEinhibitorCHEMBL2103884OPROZOMIB
5700PSMC1PROTEASEinhibitorCHEMBL325041BORTEZOMIB
5700PSMC1PROTEASEinhibitorBORTEZOMIBBORTEZOMIB
5700PSMC1PROTEASECARFILZOMIBCARFILZOMIB24524217
5700PSMC1PROTEASEinhibitorCARFILZOMIBCARFILZOMIB
Page: 1